Created: July 05, 2021 01:00 AM
The controversy of a newly approved Alzheimer’s drug not only hasn't settled down. Three members of the FDA quit over it. So what does that mean for people diagnosed with the disease? How can family members make decisions? Beth Smith Boivn, executive director of the Alzheimer's Association northeastern New York office, joins me to talk about this.
Copyright 2021 - WNYT-TV, LLC A Hubbard Broadcasting Company